Preeti Gupta Lal PhD.

Dr. Preeti Gupta Lal is the Chief Scientific Officer (CSO) of Vgenomics. She has 30+ years of research experience in the field of data science, translational medicine, and clinical biomarker implementation across various phases of clinical trial development.  Her innovative mindset and commitment to pushing the boundaries of medical science is reflected by her track record of co-inventing 150 plus patents.

Her professional journey spans across renowned healthcare companies, including Alladapt Immunotherapeutic, Roche Diagnostics, Gilead Sciences, Genentech, CareDx, and Incyte Genomics. At each organization, she has played instrumental roles in advancing translational medicine and data science initiatives, driving companion diagnostic programs, and contributing to biomarker development across various therapeutic indications. She has extensive experience in regulatory interactions with both the drug and device divisions of the FDA as well.

With a solid background in managing bioinformatics teams and collaborating with pharmaceutical partners, she brings a wealth of expertise to Vgenomics.

Research articles

Dr. Lal’s research focuses on transcriptional and translational biology.

Transcriptional signals of T-cell and corticosteroid-sensitive genes are associated with future acute cellular rejection in cardiac allografts

Background: Profiling mRNA levels of 11 informative genes expressed by circulating immune effector cells identifies cardiac allograft recipients at low risk for current moderate-severe acute cellular rejection (ACR). Methods: We conducted a nested case-control study of 104 cardiac allograft recipients to investigate the association of transcriptional profiles of blood samples with either a future rejection episode within 12 weeks of a baseline clinical sample or persistent histologic quiescence for the same time period…

Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection

Background: We have previously demonstrated that a peripheral blood transcriptional profile using 11 distinct genes predicts onset of cardiac allograft rejection weeks to months prior to the actual event. Methods: In this analysis, we ascertained the performance of this transcriptional algorithm in a Bayesian representative population: 28 cardiac transplant recipients who progressed to moderate to severe rejection; 53 who progressed to mild rejection; and 46 who remained rejection-free. Furthermore, we characterized longitudinal…

Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling

Rejection diagnosis by endomyocardial biopsy (EMB) is invasive, expensive and variable. We investigated gene expression profiling of peripheral blood mononuclear cells (PBMC) to discriminate ISHLT grade 0 rejection (quiescence) from moderate/severe rejection (ISHLT > or = 3A). Patients were followed prospectively with blood sampling at post-transplant visits. Biopsies were graded by ISHLT criteria locally and by three independent pathologists blinded to clinical data…

Astrocyte-astrocytoma cell line interactions in culture

Astrocytomas are the most common brain tumors arising in the CNS and account for 65% of all primary brain tumors. Astrocytes have been shown to have the highest predisposition to malignant transformation compared to any other CNS cell type. The majority of astrocytomas are histologically malignant neoplasm. Previous studies have shown that resident astrocytes are the first cell type to react to tumors and surround them…

Astrocytoma and Schwann cells in coculture

Glial fibrillary acidic protein (GFAP) is the principal intermediate filament protein found in mature astrocytes. Although the exact function of GFAP is poorly understood, it is presumed to stabilize the astrocyte’s cytoskeleton and help in maintaining cell shape. Previous studies from our laboratory have shown that when astrocytes were cocultured with primary Schwann cells (pSCs), astrocytes became hypertrophied and fibrous with intensely positive GFAP staining and segregated Schwann cells (SCs) into pockets…

Expression of glutamate uptake transporters after dibutyryl cyclic AMP differentiation and traumatic injury in cultured astrocytes

Our findings indicate that differentiation of primary astrocytes by dibutyryl cyclic adenosine monophosphate (dBcAMP) and scratch injury together resulted in increased glutamate transporter gene expression. Confluent primary cultures were prepared from cerebral cortex of normal new born rat pups. The primary cultures were then divided into four groups each: control and scratch-injured, and dBcAMP-treated control and scratch-injured cultures…


Preeti Gupta Lal is a co-inventor of 150+ patents.

US-9914921-B2Secreted proteins

US-8716445-B2Compositions comprising signal peptide-containing proteins

US-8148067-B2Methods for diagnosing and monitoring the status of systemic lupus erythematosus

US-8206947-B2Human transmembrane proteins

US-7645575-B2Genes useful for diagnosing and monitoring inflammation related disorders

US-2008241158-A1Human taste-specific receptor TIR3

WO-2010075249-A3A method for treating rheumatoid arthritis with b-cell antagonists

US-2014227278-A1Antibodies to human signal peptide-containing proteins

US-2016282350-A1Methods of diagnosing cancer


WO-2004067712-A3Intracellular signaling molecules

AU-2003279799-A1Proteins associated with cell growth, differentiation, and death

WO-02094990-A3Receptors and membrane-associated proteins

CA-2445366-A1Molecules for disease detection and treatment

AU-2002365195-A1Intracellular signaling molecules

AU-2003294510-A8Transporters and ion channels

WO-2004035755-A2Transporters and ion channels

EP-1390396-A2Molecules for disease detection and treatment

CA-2420105-A1Human kinases

CA-2406399-A1Human kinases

CA-2413186-A1Extracellular matrix and cell adhesion molecules

WO-03008625-A2Structural and cytoskeleton-associated proteins

AU-2002251911-A1Receptors and membrane-associated proteins

AU-2002303843-A1Secreted proteins

WO-0242330-A3Cystoskeleton-associated proteins

EP-1379628-A2Kinases and phosphatases sequences, and use thereof
AU-2002303878-A1Kinases and phosphatases
EP-1578899-A2Secreted proteins
AU-2002364926-A8Nucleic acid-associated proteins
AU-2002227352-A1Human kinases
CA-2437571-A1Receptors and membrane-associated proteins
AU-2002362935-A1Kinases and phosphatases
AU-2003211112-A1Secreted proteins
WO-02090530-A3Kinases and phosphatases
AU-2002364890-A8Molecules for disease detection and treatment
WO-03039348-A2Intracellular signaling molecules
WO-03087300-A2Secreted proteins
US-7029897-B2Human protein phosphatase 2C
AU-2002247042-A1Secreted proteins
AU-2002258657-A1Secreted proteins
AU-2003231981-A8Protein modification and maintenance molecules
WO-03006618-A2Nucleic acid-associated proteins
CA-2410084-A1Transporters and ion channels
AU-2002345422-A1Nucleic acid-associated proteins
AU-2002227279-A1Polynucleotide and polypeptide sequences of putative transporters and ion channells
AU-2002254466-A1G-protein coupled receptors
CA-2414387-A1Drug metabolizing enzymes
WO-02059312-A3Cell adhesion proteins
AU-2002258724-A1Protein modification and maintenance molecules
CA-2447647-A1Lipid-associated molecules
WO-02053719-A3Cytoskeleton-associated proteins
WO-03046151-A3Nucleic acid-associated proteins
EP-1427841-A2Nucleic acid-associated proteins
AU-2002239543-A1Molecules for disease detection and treatment
WO-02090521-A2Drug metabolizing enzymes
CA-2422497-A1Transporters and ion channels
WO-02062841-A3Secreted proteins
WO-02078420-A3Molecules for disease detection and treatment
WO-0229036-A3Lipid metabolism enzymes
EP-1497319-A2Cell adhesion and extracellular matrix proteins
EP-1423511-A2Nucleic-acid associated proteins
EP-1390391-A4Transporters and ion channels
AU-2002306448-A1Transporters and ion channels
AU-2002332573-A8Transporters and ion channels
AU-2002238070-A1Molecules for disease detection and treatment
WO-2004013293-A2Transporters and ion channels
AU-2003239871-A8Protein modification and maintenance molecules
AU-2002248210-A1Cell adhesion proteins
AU-2002303865-A1Transporters and ion channels
AU-2002243466-A1Cytoskeleton-associated proteins
AU-2002236984-A1Proteins associated with cell growth, differentiation, and death
WO-02064795-A3Putative human enzymes
AU-2002239570-A1Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
EP-1358330-A2Transporters and ion channels
WO-0250279-A2Nucleic acid-associated proteins
WO-02097032-A2Proteins associated with cell growth, differentiation, and death
EP-1434796-A2Secreted proteins
CA-2436732-A1Protein modification and maintenance molecules
EP-1385977-A2Secreted proteins
CA-2427085-A1Transmembrane proteins
CA-2443897-A1Transporters and ion channels
WO-03004615-A3Secreted proteins
CA-2434953-A1Protein modification and maintenance molecules
WO-03031568-A2Intracellular signaling molecules
CA-2453985-A1Receptors and membrane-associated proteins
EP-1412387-A2Transporters and ion channels
WO-0238602-A2Secreted proteins
EP-1409535-A2Human secreted proteins
AU-2001291011-A1Transporters and ion channels
WO-02070709-A2Molecules for disease detection and treatment
WO-03077875-A3Proteins associated with growth, differentiation, and death
AU-2002352912-A1Secreted proteins
AU-2003295824-A1Cell adhesion and extracellular matrix proteins
EP-1436383-A2Secreted proteins
EP-1444254-A2Molecules for disease detection and treatment
AU-2002364699-A1Receptors and membrane-associated proteins
WO-03016506-A2Secreted proteins
WO-03025130-A2Receptors and membrane-associated proteins
WO-2004009778-A3Kinases and phosphatases
WO-0236757-A3Enzymes involved in glycoprotein and glycolipid metabolism
AU-2002327419-A1Kinases and phosphatases
AU-2002359333-A1Nucleic acid-associated proteins
EP-1451212-A2Structural and cytoskeleton-associated proteins
AU-2001297737-A1Nucleic acid-associated proteins
CA-2448148-A1Carbohydrate-associated proteins
AU-2003268023-A1Protein modification and maintenance molecules
WO-02072861-A1Cd53 cell surface antigen
US-6692923-B2Tapasin-like protein
AU-2003205353-A1Protein modification and maintenance molecules
AU-2002351194-A1Cell adhesion and extracellular matrix proteins
WO-2004100774-A3Receptors and membrane-associated proteins
WO-02079404-A2Cytoskeleton-associated proteins
AU-2003295437-A1Receptors and membrane-associated proteins
WO-02077231-A3Nucleic acid-associated proteins
WO-02059283-A2Nucleic acid modification enzymes
WO-02072596-A1Steap-related protein
CA-2453833-A1Tnf receptor 2 related protein variant
WO-02061059-A3Carbohydrate metabolism enzymes
US-6962799-B2Microtubule-associated proteins and tubulins
WO-02068621-A3Rax-related protein
AU-2002358273-A8Nucleic acid-associated proteins
AU-2002334631-A1Immune response associated proteins
AU-2002357147-A1Transporters and ion channels
AU-2002252239-A1Steap-related protein
AU-2002255677-A1Cd53 cell surface antigen
WO-03056027-A1Carbohydrate-associated proteins
WO-02079389-A3Nucleic acid-associated proteins
AU-2002320089-A1Proteins associated with cell growth, differentiation, and death
AU-2002258520-A1Nucleic acid-associated proteins
WO-02066646-A3Neurotransmission-associated proteins
AU-2002250095-A1Neurotransmission-associated proteins
WO-03094848-A2Nucleic acid-associated proteins
AU-2002246779-A1Carbohydrate metabolism enzymes

With a decade of diverse experience under his belt, Sameer Malik, an alumnus of the Delhi School of Economics, brings a robust blend of business strategy, finance, operations, and sales expertise to Vgenomics. From kick starting his career at KPMG to founding and scaling an e-commerce startup to over $1.5 million in annual revenues, and further contributing to the startup ecosystem through his involvement in Startup Nexus and Token Amigo, Sameer has navigated through various industries, consistently playing to his strategic and operational strengths. His rich entrepreneurial journey and strategic acumen are now channeled towards advancing Vgenomics' mission in the realm of rare inborn diseases diagnostics and therapeutic solutions.

A translational biologist based in Silicon Valley, Dr. Lal brings her expertise in data science, translational medicine, clinical biomarker, and CDx implementation across all phases of clinical trials development to Vgenomics. With over 150 patents to her name, she has substantial experience in regulatory interactions with both the drug and device divisions of the FDA, and companion diagnostics (Dx) programs.

After earning her doctorate from International Center of Genetic Engineering and Biotechnology (ICGEB), Dr. Sardar embarked on a mission to transform her research findings into practical applications that could benefit rare disease patients globally. She noticed a gap in dedicated solutions for the burgeoning hub of rare diseases in India, particularly those affecting children, and co-founded Vgenomics with Dr. Preeti to develop affordable diagnostics and therapeutic solutions.

Open chat
✉ Hey! Need Help?
Can we help you?